Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 315

Results For "ENT"

10083 News Found

Sanofi Consumer Healthcare India reports robust Q4 and FY’25 growth
News | February 26, 2026

Sanofi Consumer Healthcare India reports robust Q4 and FY’25 growth

For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales


Volta Labs unveils push-button PCR-free whole genome sequencing kit
News | February 26, 2026

Volta Labs unveils push-button PCR-free whole genome sequencing kit

The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform


Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy
Biotech | February 26, 2026

Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy

Arcellx develops innovative immunotherapies for cancer and other incurable diseases


Alembic announces USFDA final approval for Efinaconazole Topical Solution, 10%
Drug Approval | February 25, 2026

Alembic announces USFDA final approval for Efinaconazole Topical Solution, 10%

Efinaconazole Topical Solution is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.


Caplin Steriles gets USFDA approval for Sodium Phosphate injection
Drug Approval | February 25, 2026

Caplin Steriles gets USFDA approval for Sodium Phosphate injection

Sodium Phosphates Injection is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake


Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL
Drug Approval | February 25, 2026

Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL

Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older


Shilpa Biologicals and SteinCares ink strategic pact to bring biosimilars to Latin America
News | February 25, 2026

Shilpa Biologicals and SteinCares ink strategic pact to bring biosimilars to Latin America

New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform


BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders
News | February 25, 2026

BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders

The announcement follows a record-setting $1.2 million accelerated LineaDNA order


UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis
News | February 25, 2026

UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis

NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production


Lupin launches generic Brivaracetam oral solution in US to treat epilepsy
News | February 25, 2026

Lupin launches generic Brivaracetam oral solution in US to treat epilepsy

Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB